Biopharm Services Limited articles
Come and see an automated biologics processing unit in operation at a one-day Symposium “Integrated Process Strategies For Regional Biopharmaceutical Supply” on March 28, 2023, Sedgefield, UK.
Looking back down the race circuit, the horses don’t seem to be moving quickly – until they come thundering past you, covering twice my height in one effortless stride. We can forget the many changes that have happened in the last 10 years in our industry
With Regeneron’s high profile, single-person, single-site, clinical trial proving successful (along with much supporting other clinical data!), will neutralising antibodies surf the second wave?
Our COVID-related blogs focus on capacity and cost of making the treatments and understanding opportunities or bottlenecks in large scale provision and new innovations. In this context, we review here the manufacturing costs at scale for nanobodies, and ask whether their production costs
As of October 2021, 6-7 billion doses of COVID-19 vaccines have been provided under emergency measures. The vaccines roll out has peaked at 45 million doses/day and has remained broadly stable (Our Word in Data & WHO), so we can assume that this is the current global manufacturing capacity. But with only 35% of the worlds’ population fully vaccinated, we must also assume, along with conclusions from a recent slew of pandemic preparedness reports
The growing pipeline of cell and gene therapy therapies has led to an increase in demand for gene delivery vehicles such as plasmid DNA (pDNA), messenger RNA (mRNA) and viral vectors. They can be used as stand-alone treatments or can be used as starting materials required for further processing of cell and gene therapeutics. When used as starting materials, they have been shown to have a significant impact on the cost of final cell and gene therapy products.
Determining